Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Singh, Desh Deepak | - |
dc.contributor.author | Lee, Hae-Jeung | - |
dc.contributor.author | Yadav, Dharmendra Kumar | - |
dc.date.accessioned | 2023-01-19T01:41:57Z | - |
dc.date.available | 2023-01-19T01:41:57Z | - |
dc.date.created | 2023-01-18 | - |
dc.date.issued | 2022-12 | - |
dc.identifier.issn | 1663-9812 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/86700 | - |
dc.description.abstract | Breast cancer (BC) is caused by epigenetic modifications and genetic heterogeneity and exhibits various histological feature. HER2+ (Human epidermal growth factor receptor 2) is a more aggressive type of breast cancer, diagnosis and prognosis are difficult for HER2+ BC. Anti-HER2+ inhibitors have been effectively used for patient treatment. High mortality rate is reported in HER2+ BC, due to availability of limited therapeutic options. Despite advances in systemic medications to treat metastatic breast cancer (MBC), HER2-positive MBC is still challenging for patients and treating clinicians. The clinical characteristics of the disease have changed after treatment with HER2-targeted therapy. Various types of Tyrosine kinase inhibitors (TKIs) have been developed to treat patients with HER2+ BC including afatinib, lapatinib, neratinib, tucatinib, and pyrotinib, have been developed as HER2-targeted therapies. The antibody-drug conjugates adotrastuzumab, emtansine, famtrastuzumab, and deruxtecan, as well as the anti-HER2 monoclonal antibody pertuzumab are used in both early-stage and metastatic situations, either alone or in conjunction with chemotherapy and other HER2-targeting therapies. The emergence of drug resistance in antiHER2 therapies has been observed. To overcome drug resistance and limited efficacy in current treatment options, nano formulations can be used in patients with HER2+ BC treatment. Anti-HER2 ligands can be used in various nano formulations to target HER2 receptors. Here we will discuss, targeted TKIs in patients with HER2+ BC, clinical studies of HER2+ targeted TKIs, mechanisms of resistance to HER2-directed therapies with new implications of TKIs in HER2+ MBC (metastatic breast cancer) and anti-HER2 ligand in various nano formulations to target HER2 receptors. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.relation.isPartOf | FRONTIERS IN PHARMACOLOGY | - |
dc.title | Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000903825000001 | - |
dc.identifier.doi | 10.3389/fphar.2022.1089066 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN PHARMACOLOGY, v.13 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85144965688 | - |
dc.citation.title | FRONTIERS IN PHARMACOLOGY | - |
dc.citation.volume | 13 | - |
dc.contributor.affiliatedAuthor | Lee, Hae-Jeung | - |
dc.contributor.affiliatedAuthor | Yadav, Dharmendra Kumar | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | breast cancer | - |
dc.subject.keywordAuthor | HER2-positive | - |
dc.subject.keywordAuthor | tyrosine kinase inhibitors | - |
dc.subject.keywordAuthor | novel combinations | - |
dc.subject.keywordAuthor | clinical practice | - |
dc.subject.keywordPlus | TARGETED DRUG-DELIVERY | - |
dc.subject.keywordPlus | TRASTUZUMAB EMTANSINE | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | LAPATINIB | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | HER2 | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | PERTUZUMAB | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.